Given the observed efficacy of allosteric LSD1 inhibitors in many sarcomas in addition to the elevated expression of LSD1, determining the nonenzymatic function of LSD1 in these fusion-driven tumors is critically important, especially as these inhibitors progress into the clinic. The gene discussed is KDM1A; the disease is sarcoma.